Omcazio is a drug owned by Handa Oncology Llc. It is protected by 6 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2044. Details of Omcazio's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12415784 | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | Active |
| US12741938 | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | Active |
| US12516025 | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | Active |
| US12552567 | Method For Packaging Articles In Boxes And Packaging Device Operating According To Such A Method |
Jan, 2044
(17 years from now) | Active |
| US12552749 | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | Active |
| US12064430 | Kinase Inhibitor Salts And Compositions Thereof |
Jun, 2039
(12 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Omcazio is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Omcazio's family patents as well as insights into
ongoing legal events
on those patents.
Omcazio's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Omcazio's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 30, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Omcazio Generics:
There are no approved generic versions for Omcazio as of now.
Alternative Brands for Omcazio
There are several other brand drugs in the same treatment category as Omcazio. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bayer Hlthcare |
| |||
| Exelixis Inc |
| |||
About Omcazio
Omcazio is a drug owned by Handa Oncology Llc. Omcazio uses Cabozantinib Laurylsulfate as an active ingredient. Omcazio was launched by Handa Oncol in 2026.
Approval Date:
Omcazio was approved by FDA for market use on 03 September, 2026.
Active Ingredient:
Omcazio uses Cabozantinib Laurylsulfate as the active ingredient. Check out other Drugs and Companies using Cabozantinib Laurylsulfate ingredient
Dosage:
Omcazio is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 23MG BASE | CAPSULE | Prescription | ORAL |
| EQ 11.5MG BASE | CAPSULE | Prescription | ORAL |
| EQ 34.5MG BASE | CAPSULE | Prescription | ORAL |